Geode Capital Management
RXRX icon

Geode Capital Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Geode Capital Management’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$50.7M Buy
13,819,135
+1,544,051
+13% +$5.14M ﹤0.01% 1619
2026
Q1 		$37.7M Buy
12,275,084
+1,340,832
+12% +$5.18M ﹤0.01% 1653
2025
Q4 		$44.7M Buy
10,934,252
+1,310,695
+14% +$6.49M ﹤0.01% 1556
2025
Q3 		$47M Buy
9,623,557
+1,847,149
+24% +$9.7M ﹤0.01% 1501
2025
Q2 		$39.4M Buy
7,776,408
+1,332,428
+21% +$6.55M ﹤0.01% 1555
2025
Q1 		$34.1M Buy
6,443,980
+356,831
+6% +$2.6M ﹤0.01% 1596
2024
Q4 		$41.2M Buy
6,087,149
+655,238
+12% +$4.41M ﹤0.01% 1553
2024
Q3 		$35.8M Buy
5,431,911
+656,003
+14% +$4.7M ﹤0.01% 1649
2024
Q2 		$35.8M Buy
4,775,908
+1,324,743
+38% +$11.6M ﹤0.01% 1583
2024
Q1 		$34.4M Buy
3,451,165
+125,180
+4% +$1.39M ﹤0.01% 1601
2023
Q4 		$32.8M Buy
3,325,985
+187,295
+6% +$1.34M ﹤0.01% 1618
2023
Q3 		$24M Buy
3,138,690
+329,547
+12% +$3.29M ﹤0.01% 1706
2023
Q2 		$21M Buy
2,809,143
+65,659
+2% +$459K ﹤0.01% 1821
2023
Q1 		$18.3M Buy
2,743,484
+133,536
+5% +$1.06M ﹤0.01% 1866
2022
Q4 		$20.1M Buy
2,609,948
+277,865
+12% +$2.72M ﹤0.01% 1768
2022
Q3 		$24.8M Buy
2,332,083
+826,087
+55% +$8.37M ﹤0.01% 1575
2022
Q2 		$12.3M Buy
1,505,996
+212,240
+16% +$1.42M ﹤0.01% 2115
2022
Q1 		$9.26M Sell
1,293,756
-1,201
-0.1% -$12.8K ﹤0.01% 2394
2021
Q4 		$22.2M Buy
1,294,957
+732,626
+130% +$13.8M ﹤0.01% 1885
2021
Q3 		$12.9M Buy
562,331
+65,382
+13% +$1.85M ﹤0.01% 2272
2021
Q2 		$18.1M Buy
+496,949
New +$14.7M ﹤0.01% 2034

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Geode Capital Management's RXRX Position: Q2 2026 in Review

Geode Capital Management increased its Recursion Pharmaceuticals (RXRX) stake by 13% in Q2 2026, buying an estimated $5.14M and bringing the position to 13,819,135 shares worth $50.7M. The position accounts for ﹤0.01% of the portfolio, ranked #1619.

Geode Capital Management first reported a position in RXRX in Q2 2021 and has held it in 21 quarters since. 342 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Geode Capital Management held 13,819,135 shares of Recursion Pharmaceuticals worth $50.7M as of Q2 2026.
  • Geode Capital Management bought 1,544,051 Recursion Pharmaceuticals shares in Q2 2026, an estimated $5.14M.
  • Recursion Pharmaceuticals made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #1619 holding.
  • Geode Capital Management first reported a position in Recursion Pharmaceuticals in Q2 2021 and has held it in 21 quarters since.
  • 342 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.